Scienture Holdings Inc (SCNX)

$0.34 -0.01 (-3.45%)
Market Cap 13.98M
Revenue (ttm) 430,000.00
Net Income (ttm) -41.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,653.49%
Debt to Equity Ratio 0.00
Volume 277,600
Avg Vol 375,724
Day's Range N/A - N/A
Shares Out 40.63M
Stochastic %K 16%
Beta 3.28
Analysts Strong Sell
Price Target $1.50

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dih...

Industry: Pharmaceutical Retailers
Sector: Healthcare
Phone: 631) 670-6039
Address:
20 Austin Boulevard, Commack, United States
pudge83
pudge83 Jul. 2 at 6:58 PM
$SCNX I will never get in another pharmaceutical stock
1 · Reply
BEATWALLSTREET
BEATWALLSTREET Jul. 1 at 10:05 PM
$SCNX added 10k shares today and from what I'm seeing with micro caps lately, I'm not selling my shares for anything less than $10. I'm sure it'll be a bumpy ride with plenty of ups and downs, but I've got the time to wait
0 · Reply
Ottersberger
Ottersberger Jul. 1 at 1:48 PM
$SCNX buys coming in
0 · Reply
Ottersberger
Ottersberger Jul. 1 at 12:57 PM
$SCNX I wrote IR 3 times….no response…is the position as IR manager at all occupied?
1 · Reply
Diverstj981
Diverstj981 Jun. 29 at 3:25 PM
$SCNX Uuugggghhh
0 · Reply
Ottersberger
Ottersberger Jun. 28 at 12:40 PM
$SCNX one week closer to mid july - cross fingers they don’t postpone the launch again
1 · Reply
Diverstj981
Diverstj981 Jun. 26 at 11:34 AM
$SCNX ?????????
0 · Reply
Omar_w
Omar_w Jun. 25 at 6:18 PM
$SCNX Given the prolonged underperformance of the stock, it may be appropriate for the current CEO to step down and allow new leadership to drive shareholder value
0 · Reply
Mo_Better
Mo_Better Jun. 25 at 3:41 PM
$SCNX management must feel there is a good chance of the market sustaining the share price above $1 as revenues increase. Would make sense to hold good news in reserve )if possible) until needed.
0 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 24 at 9:13 PM
$SCNX They're probably diluting. A stock doesn't usually keep fading lower on nothing but good news unless there's selling pressure coming from somewhere.
0 · Reply
Latest News on SCNX
Scienture announces progress in commercialization of Arbli

2026-06-18T12:30:57.000Z - 16 days ago

Scienture announces progress in commercialization of Arbli

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

Jun 18, 2026, 8:05 AM EDT - 16 days ago

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Jun 9, 2026, 8:05 AM EDT - 25 days ago

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

Jun 4, 2026, 8:00 AM EDT - 4 weeks ago

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

Scienture reveives U.S. patent covering Rezenopy Nasal Spray

2026-06-02T15:04:18.000Z - 4 weeks ago

Scienture reveives U.S. patent covering Rezenopy Nasal Spray

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

Jun 2, 2026, 8:05 AM EDT - 4 weeks ago

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

May 18, 2026, 8:38 AM EDT - 6 weeks ago

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

May 7, 2026, 8:05 AM EDT - 2 months ago

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

Scienture announces third patent granted for Arbli

2026-05-07T03:50:06.000Z - 2 months ago

Scienture announces third patent granted for Arbli

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

May 6, 2026, 8:05 AM EDT - 2 months ago

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

Scienture granted 180-day extension to meet Nasdaq minimum bid price

2026-04-15T13:37:53.000Z - 2 months ago

Scienture granted 180-day extension to meet Nasdaq minimum bid price

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 8:07 AM EDT - 3 months ago

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Why Is Scienture Holdings Stock (SCNX) Up Today?

2026-03-11T13:15:15.000Z - 4 months ago

Why Is Scienture Holdings Stock (SCNX) Up Today?

Scienture formalized multiple GPO agreements for Rezenopy

2026-03-11T12:16:19.000Z - 4 months ago

Scienture formalized multiple GPO agreements for Rezenopy

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Mar 11, 2026, 8:05 AM EDT - 4 months ago

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Scienture initiated with a Buy at Maxim

2026-02-24T13:33:22.000Z - 4 months ago

Scienture initiated with a Buy at Maxim

Scienture initiated with a Buy at Maxim

2026-02-24T13:27:59.000Z - 4 months ago

Scienture initiated with a Buy at Maxim

Scienture provides commercial update on Arbli

2026-02-03T13:11:18.000Z - 5 months ago

Scienture provides commercial update on Arbli

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Feb 3, 2026, 8:05 AM EST - 5 months ago

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Scienture announces USPTO issues patent covering REZENOPY Nasal Spray

2026-01-14T13:10:22.000Z - 6 months ago

Scienture announces USPTO issues patent covering REZENOPY Nasal Spray

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Jan 14, 2026, 8:05 AM EST - 6 months ago

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Scienture provides update on commercial launch of REZENOPY

2025-12-22T13:15:28.000Z - 6 months ago

Scienture provides update on commercial launch of REZENOPY

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Dec 22, 2025, 8:05 AM EST - 6 months ago

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

2025-12-10T13:20:49.000Z - 7 months ago

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Dec 10, 2025, 8:05 AM EST - 7 months ago

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Dec 2, 2025, 8:05 AM EST - 7 months ago

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Scienture reports Q3 EPS (19c) vs. ($1.34) last year

2025-11-13T13:15:24.000Z - 8 months ago

Scienture reports Q3 EPS (19c) vs. ($1.34) last year

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Nov 13, 2025, 8:05 AM EST - 8 months ago

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Scienture announces addition of Arbli to formularies of national health plans

2025-11-04T13:30:45.000Z - 8 months ago

Scienture announces addition of Arbli to formularies of national health plans

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Nov 4, 2025, 8:05 AM EST - 8 months ago

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Why Did Scienture Stock (SCNX) Soar 45% Today?

2025-10-23T13:06:05.000Z - 9 months ago

Why Did Scienture Stock (SCNX) Soar 45% Today?

Scienture starts commercial sales, fulfillment of first orders of Arbli

2025-10-23T12:26:28.000Z - 9 months ago

Scienture starts commercial sales, fulfillment of first orders of Arbli

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Oct 23, 2025, 8:05 AM EDT - 9 months ago

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Scienture’s Arbli is commercially available through wholesalers nationwide

2025-10-16T13:06:15.000Z - 9 months ago

Scienture’s Arbli is commercially available through wholesalers nationwide

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Oct 16, 2025, 9:00 AM EDT - 9 months ago

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Wellgistics Health Announces Executive Management and Board Changes

Oct 13, 2025, 8:00 AM EDT - 9 months ago

Wellgistics Health Announces Executive Management and Board Changes

WGRX

Scienture announces repayment, conversion of outstanding debentures

2025-10-08T13:15:30.000Z - 9 months ago

Scienture announces repayment, conversion of outstanding debentures

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Sep 16, 2025, 8:05 AM EDT - 10 months ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Aug 14, 2025, 9:00 AM EDT - 11 months ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Aug 13, 2025, 8:05 AM EDT - 11 months ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 24, 2025, 5:12 PM EDT - 1 year ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Jul 16, 2025, 8:15 AM EDT - 1 year ago

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Scienture Holdings Announces Cancelation of ELOC

Jun 17, 2025, 8:05 AM EDT - 1 year ago

Scienture Holdings Announces Cancelation of ELOC

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

May 28, 2025, 7:45 AM EDT - 1 year ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

SCIENTURE Announces Executive Leadership Transition

May 22, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE Announces Executive Leadership Transition

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

May 19, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 22, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 8, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Apr 3, 2025, 8:26 AM EDT - 1 year ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 25, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 18, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Mar 6, 2025, 7:40 AM EST - 1 year ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Jan 21, 2025, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 17, 2024, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Dec 10, 2024, 8:05 AM EST - 1 year ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 24, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Sep 20, 2024, 11:59 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Aug 5, 2024, 8:01 AM EDT - 2 years ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 26, 2024, 8:01 AM EDT - 2 years ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

TRxADE Health, Inc. Announces Special Cash Dividend

Jul 9, 2024, 8:05 AM EDT - 2 years ago

TRxADE Health, Inc. Announces Special Cash Dividend

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

May 29, 2024, 4:05 PM EDT - 2 years ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Apr 23, 2024, 4:05 PM EDT - 2 years ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Scienture Holdings Annual report: Q4 2023

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Scienture Holdings Annual report: Q4 2023

Trxade health, Inc files its 3Q 10Q

Jan 17, 2024, 9:07 AM EST - 2 years ago

Trxade health, Inc files its 3Q 10Q

Scienture Holdings Quarterly report: Q3 2023

Jan 16, 2024, 7:00 AM EST - 2 years ago

Scienture Holdings Quarterly report: Q3 2023

Scienture Holdings Earnings release: Q3 2023

Jan 16, 2024, 7:00 AM EST - 2 years ago

Scienture Holdings Earnings release: Q3 2023

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Nov 29, 2023, 6:13 PM EST - 2 years ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 17, 2023, 8:05 AM EDT - 2 years ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 12, 2023, 8:05 AM EDT - 2 years ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Oct 4, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

pudge83
pudge83 Jul. 2 at 6:58 PM
$SCNX I will never get in another pharmaceutical stock
1 · Reply
BEATWALLSTREET
BEATWALLSTREET Jul. 1 at 10:05 PM
$SCNX added 10k shares today and from what I'm seeing with micro caps lately, I'm not selling my shares for anything less than $10. I'm sure it'll be a bumpy ride with plenty of ups and downs, but I've got the time to wait
0 · Reply
Ottersberger
Ottersberger Jul. 1 at 1:48 PM
$SCNX buys coming in
0 · Reply
Ottersberger
Ottersberger Jul. 1 at 12:57 PM
$SCNX I wrote IR 3 times….no response…is the position as IR manager at all occupied?
1 · Reply
Diverstj981
Diverstj981 Jun. 29 at 3:25 PM
$SCNX Uuugggghhh
0 · Reply
Ottersberger
Ottersberger Jun. 28 at 12:40 PM
$SCNX one week closer to mid july - cross fingers they don’t postpone the launch again
1 · Reply
Diverstj981
Diverstj981 Jun. 26 at 11:34 AM
$SCNX ?????????
0 · Reply
Omar_w
Omar_w Jun. 25 at 6:18 PM
$SCNX Given the prolonged underperformance of the stock, it may be appropriate for the current CEO to step down and allow new leadership to drive shareholder value
0 · Reply
Mo_Better
Mo_Better Jun. 25 at 3:41 PM
$SCNX management must feel there is a good chance of the market sustaining the share price above $1 as revenues increase. Would make sense to hold good news in reserve )if possible) until needed.
0 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 24 at 9:13 PM
$SCNX They're probably diluting. A stock doesn't usually keep fading lower on nothing but good news unless there's selling pressure coming from somewhere.
0 · Reply
Vincent6768
Vincent6768 Jun. 24 at 1:45 PM
$SCNX Halted?
2 · Reply
Lyn30
Lyn30 Jun. 23 at 6:58 PM
$SCNX IMO This stock has a pattern everytime when it comes to a point then bounce huge
0 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 23 at 6:54 PM
$SCNX
0 · Reply
Lyn30
Lyn30 Jun. 23 at 1:28 PM
$SCNX My Target 1.50 whenever it goes
0 · Reply
Marketmoverjoe
Marketmoverjoe Jun. 18 at 9:35 PM
$SCNX been holding this for a bit. Seems like some nice movement. I'd be happy to see .50
0 · Reply
Ottersberger
Ottersberger Jun. 18 at 8:05 PM
$SCNX someone sold big in the last minute….
1 · Reply
Jawick
Jawick Jun. 18 at 2:22 PM
$SCNX let's play the lottery and this stock hits 10 bucks not to be greedy
0 · Reply
Huskersnsaints
Huskersnsaints Jun. 18 at 2:01 PM
$SCNX i'm not looking for a rapid movement upward!!! I'm just looking for a reversal from the Years worth of downward price trending!!!! I can't believe this stock appears to be going unnoticed!!!!!
1 · Reply
Ottersberger
Ottersberger Jun. 18 at 1:42 PM
$SCNX 28k wall at .4050🤮
1 · Reply
ProfessorDman1
ProfessorDman1 Jun. 18 at 1:10 PM
$SCNX .50 cents break next …
1 · Reply
Ottersberger
Ottersberger Jun. 18 at 1:04 PM
$SCNX again fluff news which will not drive the price sustainable up We need real orders
0 · Reply
Huskersnsaints
Huskersnsaints Jun. 18 at 1:03 PM
$SCNX This stock for what ever reason just will not move up on good news So many scams out there that move up 100-1000% but you get a company with decent business model and get gets destroyed!!!! SO MUCH CORRUPTION
0 · Reply